objective O O
: O O
this O O
study O O
aimed O O
to O O
determine O O
the O O
effect O O
of O O
external T O
beam T O
radiation T T
therapy T T
on O O
choroidal D D
neovascularization D D
( D D
cnv D D
) D D
secondary O D
to O D
age-related D D
macular D D
degeneration D D
( D O
amd D O
) D O

thrombolytic T T
therapy T T
has O O
been O O
accepted O O
in O O
the O O
treatment O O
of O O
acute D D
myocardial D D
infarction D D

a O O
bolus O O
infusion O O
of O O
tissue T O
plasminogen T O
activator T O
was O O
administered O O
during O O
cpr T O
in O O
refractory D O
ventricular D O
fibrillation D O
( O O
two O O
cases O O
) O O
and O O
pulseless D O
ventricular D O
tachycardia D O
( O O
one O O
case O O
) O O

we O O
conclude O O
that O O
bolus T O
thrombolytic T T
infusions T T
during O O
cpr D O
may O O
facilitate O O
spontaneous O O
return O O
of O O
circulation O O
in O O
select O O
patients O O
with O O
confirmed D O
acute D D
myocardial D D
infarction D D
, O O
witnessed O O
cardiac D O
arrest D O
in O O
the O O
ed O O
, O O
and O O
refractory D O
ventricular D O
fibrillation D O
or O O
tachycardia D O

< O O
to_see O O
> O O
case O O
summary O O
: O O
a O O
92-year O O
old O O
white O O
woman O O
who O O
was O O
receiving O O
venlafaxine T T
for O O
management O O
of O O
depression D O
was O O
found O O
to O O
have O O
hyponatremia O O

touch O O
sensibility O O
was O O
assessed O O
with O O
von O O
frey O O
's O O
monofilaments O O
in O O
the O O
breasts O O
of O O
10 O O
healthy O O
women O O
( O O
controls O O
) O O
and O O
of O O
80 O O
women O O
with O O
breast D D
cancer D D
who O O
at O O
least O O
1 O O
year O O
previously O O
had O O
undergone O T
subcutaneous T T
mastectomy T T
and O O
immediate O O
reconstruction O O
with O O
a O O
prosthesis O O

although O O
improved O O
glycemic T T
control T T
, O O
maintenance O O
of O O
normal O O
blood O O
pressure O O
, O O
and O O
use O O
of O O
angiotensin-converting T O
enzyme T O
inhibitors T O
are O O
important O O
strategies O O
to O O
avoid O O
developing O O
microalbuminuria D O
, O O
dietary O O
macronutrient O O
intake O O
may O O
also O O
play O O
a O O
role O O

local O T
injection O T
of O T
corticosteroids T T
into O O
refractory O D
esophageal O D
strictures O D
to O D
decrease O D
the O D
restenosis D D
rate O O
has O O
been O O
reported O O

we O O
systematically O O
reviewed O O
the O O
evidence O O
concerning O O
the O O
ability O O
of O O
five O O
systemic T O
treatments T O
to O O
induce O O
remission O O
in O O
patients O O
with O O
severe D O
psoriasis D D
: O O
ultraviolet T O
b T O
( T O
uvb T O
) T O
, O O
photochemotherapy T O
( T O
puva T O
) T O
, O O
methotrexate T O
( T O
mtx T O
) T O
, O O
retinoids T O
( T O
ret T O
) T O
and O O
cyclosporin T O
a T O
( T O
cya T O
) T O

consequently O O
, O O
parenteral T O
nutrition T O
( T O
pn T O
) T O
solutions T O
used O O
to O O
treat O O
malnourished O O
patients O O
with O O
chronic D D
renal D D
failure D D
usually O O
are O O
prepared O O
with O O
little O O
supplementation O O
of O O
these O O
cations O O

< O O
to_see O O
> O O
conclusions O O
: O O
malnourished O O
patients O O
with O O
chronic D D
renal D D
failure D D
receiving O O
pn T O
are O O
at O O
risk O O
of O O
developing O O
electrolyte D O
abnormalities D O
, O O
particularly O O
hypophosphatemia D O

purpose O O
: O O
we O O
report O O
a O O
multicenter O O
experience O O
using O O
tubularized T O
incised T O
plate T O
urethroplastym T O
for O O
proximal D O
hypospadias D O

materials O O
and O O
methods O O
: O O
from O O
august O O
1993 O O
to O O
december O O
1996 O O
tubularized T O
incised T O
plate T O
urethroplasty T O
was O O
performed O O
in O O
27 O O
boys O O
6 O O
months O O
to O O
3 O O
years O O
old O O
with O O
mid D O
shaft D O
and D O
penoscrotal D O
hypospadias D O

results O O
: O O
tubularized T O
incised T O
plate T O
surgery T T
created O T
a O O
functional O O
neourethra O O
even O O
in O O
penoscrotal D O
hypospadias D O

conclusions O O
: O O
tubularized T O
incised T O
plate T O
urethroplasty T O
is O O
a O O
versatile O O
operation O O
that O O
corrects O D
proximal D D
hypospadias D D
defects D D
with O O
few O O
complications O O
and O O
superior O O
cosmetic O O
results O O

aortocoronary T T
bypass T T
grafting T T
is O O
an O O
accepted O O
procedure O O
for O O
ischemic D D
heart D D
disease D D

immunotherapy T O
of O O
mice O O
with O O
preexisting O O
cancers D D
with O O
heat T O
shock T D
protein T D
preparations T D
derived T O
from T O
autologous T O
cancer T O
resulted O O
in O O
retarded O O
progression O O
of O O
the O O
primary O D
cancer D D
, O O
a O O
reduced O O
metastatic O D
load O D
, O O
and O O
prolongation O O
of O O
life-span O O

< O O
to_see O O
> O O
intrapleural T D
injection T D
of T D
irradiated T D
llc-il2 T D
cured O D
pre-existing D D
lung D D
llc D D
tumors D D
and O O
extended O O
the O O
survival O O
of O O
the O O
mice O O
but O O
did O O
not O O
affect O O
survival O O
of O O
mice O O
with O O
pre-existing O D
peritoneal D D
tumors D D
nor O O
did O O
it O O
affect O O
the O O
growth O O
of O O
s.c. D D
tumors D D

< O O
to_see O O
> O O
intraperitoneal T D
injection T D
of T D
irradiated T D
llc-il2 T D
cured O D
pre-existing D D
llc D D
peritoneal D D
tumors D D
and O O
extended O O
the O O
survival O O
of O O
the O O
mice O O
but O O
did O O
not O O
affect O O
survival O O
of O O
mice O D
bearing O D
lung D D
tumors D D
nor O O
did O O
it O O
affect O O
the O O
growth O O
of O O
s.c. D D
tumors D D

subcutaneous T T
injection T T
of T O
irradiated T O
llc-il2 T O
did O O
not O O
affect O O
the O O
growth O O
of O O
preexisting O O
s.c. D D
tumors D D
and O O
also O O
did O O
not O O
improve O O
survival O O
of O O
mice O O
bearing O O
the O O
lung D O
or D O
peritoneal D D
tumors D D

we O O
describe O O
such O O
an O O
event O O
in O O
a O O
man O O
who O O
underwent O O
allogeneic T O
bmt T O
for O O
apl D O
in O O
second O O
relapse O O
and O O
4 O O
years O O
later O O
presented O O
with O O
testicular O O
relapse O O

olanzapine T O
is O O
an O O
atypical O O
antipsychotic O O
effective O O
in O O
the O O
treatment O O
of O O
schizophrenic D O
patients D O

after O O
a O O
2- O O
to O O
9-day O O
placebo O O
lead-in O O
, O O
79 O O
inpatients O O
with O O
schizophrenia D D
according O O
to O O
dsm-iii-r O O
criteria O O
were O O
placed O O
on O O
an O O
olanzapine T O
dosage O O
of O O
10 O O
mg/day O O
or O O
1 O O
mg/day O O
for O O
up O O
to O O
6 O O
weeks O O

fludarabine T O
and O O
ara-c T D
successfully O D
eradicated O D
bone D D
marrow D D
disease D D
in O O
16 O O
of O O
27 O O
patients O O
( O O
59 O O
% O O
) O O
, O O
23 O O
patients O O
of O O
which O O
had O O
been O O
treated O O
previously O O
with O O
high-dose O O
ara-c T O

these O O
results O O
verified O O
the O O
synergistic O O
effect O O
fludarabine T O
exhibited O O
in O O
augmenting O O
ara-ctp T O
concentrations O O
in O O
patients O O
' O O
leukemic O O
blasts O O
, O O
thus O O
improving O O
the O O
clinical O O
response O O
in O O
relapsed D O
pediatric D O
leukemias D O

background O O
: O O
the O O
growing O O
use O O
of O O
heparin T T
in O O
acute D D
thrombotic D D
disorders D D
, O O
coupled O O
with O O
the O O
availability O O
of O O
many O O
new O O
antithrombotic T O
agents T O
, O O
emphasizes O O
the O O
need O O
for O O
adequate O O
characterization O O
of O O
the O O
platelet O O
effects O O
of O O
the O O
various O O
anticoagulants T O

methods O O
and O O
results O O
: O O
platelet O O
p-selectin O O
( O O
cd62 O O
) O O
and O O
activated O O
gp O O
iib/iiia O O
( O O
pac-1 O O
) O O
expression O O
on O O
platelet O O
membrane O O
was O O
quantified O O
in O O
whole O O
blood O O
as O O
well O O
as O O
platelet O O
aggregation O O
in O O
platelet-rich O O
plasma O O
in O O
43 O O
patients O O
with O O
unstable D D
angina D D
before O O
and O O
during O O
treatment O O
with O O
ufh T O
or O O
enoxaparin T T

purpose O O
: O O
we O O
review O O
our O O
initial O O
experience O O
with O O
direct T O
percutaneous T O
transluminal T O
angioplasty T O
( T O
pta T O
) T O
as O O
a O O
reperfusion T O
treatment T O
for O O
acute D D
occlusion D D
of D D
the D D
middle D D
cerebral D D
artery D O

< O O
to_see O O
> O O
conclusion O O
: O O
direct O O
pta O O
may O O
be O O
performed O O
safely O O
as O O
an O O
alternative O O
to O O
thrombolytic O T
therapy O T
in O O
patients O O
with O O
acute O D
occlusion O D
of O D
the O D
middle O D
cerebral O D
artery O O
when O O
early O O
ct O O
findings O O
and/or O O
lenticulostriate O O
artery O O
involvement O O
are O O
present O O
or O O
when O O
superselective O O
local O O
angiography O O
shows O O
the O O
presence O O
of O O
a O O
large O O
embolus O O
or O O
high-grade O O
stenosis O O

women O O
randomised O O
to O O
screen-and-treat O O
received O O
appropriate O O
antibiotics T T
only O O
if O O
screening O O
proved O O
positive O O
for O O
one O O
or O O
more O O
infection D D

< O O
to_see O O
> O O
a O O
71-year-old O O
woman O O
with O O
autoimmune O D
hemolytic O D
anemia O D
underwent O O
an O O
emergency O O
endocardial T O
patch T O
repair T O
for O O
ventricular D O
septal D O
perforation D O
after O O
acute O D
myocardial O D
infarction O D

use O O
of O O
washed T O
red T O
blood T O
cells T O
was O O
effective O O
in O O
averting O O
hemolytic D D
crisis D D
throughout O O
perioperative O O
period O O

therefore O O
, O O
prudent O O
management O O
and O O
use O O
of O O
washed T O
red T O
blood T O
cells T O
transfusion T O
would O O
prevent O O
hemolytic D D
aggravation D D
even O O
in O O
open O T
heart O T
surgery O T

< O O
to_see O O
> O O
we O O
report O O
a O O
case O O
of O O
a O O
29-year-old O O
male O O
chronic O O
hbv O O
carrier O O
who O O
developed O O
fulminant D D
reactivated D D
hbv D D
infection D D
following O O
intensive O T
chemotherapy T T
for O O
stage D D
ivb D D
large D D
cell D D
b-cell D D
non-hodgkin D D
's D D
lymphoma D D
associated O O
with O O
extensive O O
central O O
nervous O O
system O O
and O O
bone O O
marrow O O
involvement O O

we O O
advise O O
that O O
lamivudine T O
should O O
be O O
considered O O
during O O
intensive O T
chemotherapy T T
treatment T T
of O O
chronic O O
carriers O O
of O O
hbv D O

objectives O O
: O O
the O O
purpose O O
of O O
this O O
analysis O O
was O O
to O O
determine O O
the O O
influence O O
of O O
an O O
additional O O
treatment O O
delay O O
inherent O O
in O O
transfer O O
to O O
an O O
angioplasty O O
center O O
for O O
primary T O
angioplasty T O
of O O
patients O O
with O O
acute D D
myocardial D D
infarction D D
who O O
are O O
first O O
admitted O O
to O O
hospitals O O
without O O
angioplasty O O
facilities O O

background O O
: O O
several O O
randomized O O
trials O O
have O O
demonstrated O O
the O O
benefits O O
of O O
primary T O
angioplasty T O
in O O
acute D D
myocardial D D
infarction D D

we O O
report O O
the O O
first O O
case O O
( O O
to O O
our O O
knowledge O O
) O O
of O O
an O O
endoscopic T O
removal T O
of O O
a O O
forehead D O
soft D O
tissue D O
mass D O

as O O
the O O
overview O O
shows O O
, O O
both O O
groups O O
of O O
substances O O
are O O
useful O O
for O O
individualized O O
treatment O O
of O O
benign D O
prostatic D O
hyperplasia D O
( D O
bph D O
) D O
, O O
provided O O
that O O
conservative O O
pharmacological T O
treatment T O
of O O
bph D O
is O O
basically O O
accepted O O
and O O
that O O
the O O
patients O O
' O O
quality O O
of O O
life O O
is O O
also O O
considered O O

the O O
results O O
of O O
several O O
clinical O O
investigations O O
showed O O
the O O
efficacy O O
and O O
safety O O
of O O
artichoke T O
extracts T O
( T O
cynara T O
scolymus T O
l. T O
) T O
in O O
the O O
treatment O O
of O O
hepato-biliary D O
dysfunction D O
and D O
digestive D O
complaints D O
, O O
such O O
as O O
sensation O O
of O O
fullness O O
, O O
loss D O
of D O
appetite D O
, O O
nausea D O
and O O
abdominal D D
pain D D

besides O O
the O O
well-known O O
nonsteroidal T O
antiinflammatory T O
drugs T O
( T O
nsaid T O
) T O
for O O
the O O
treatment O O
of O O
rheumatic D D
pain D D
herbal T D
medicine T O
can O O
also O O
be O O
applied O O
successfully O O

extracts O O
of O O
the O O
secondary O O
tubers O O
of O O
devil T O
's T O
claw T O
( T O
harpagophytum T O
procumbens T O
) T O
are O O
recommended O O
for O O
the O O
supportive O T
treatment O T
of O O
degenerative D O
painful D O
rheumatism D O

high-dose T O
intravenous T O
immunoglobulin T O
( T O
hdivig T O
) T O
is O O
increasingly O O
used O O
to O O
treat O O
a O O
range O O
of O O
inflammatory D O
and D O
autoimmune D D
diseases D D

the O O
current O O
dermatological O O
uses O O
of O O
hdivig T O
include O O
the O O
treatment O O
of O O
dermatomyositis D O
and O O
the O O
autoimmune D D
bullous D D
disorders D D
, O O
epidermolysis D O
bullosa D O
acquisita D O
, O O
pemphigoid D O
, O O
and O O
pemphigus D O

unfortunately O O
, O O
current O O
dermatological O O
uses O O
of O O
hdivig O O
have O O
been O O
limited O O
to O O
either O O
uncontrolled O O
trials O O
or O O
anecdotal O O
case O O
reports O O
, O O
except O O
for O O
a O O
single O O
controlled O O
trial O O
of O O
hdivig T O
as O O
adjunctive O O
therapy O O
in O O
patients O O
with O O
dermatomyositis D O
, O O
which O O
documented O O
a O O
significant O O
benefit O O

we O O
describe O O
a O O
technique O O
that O O
enables O O
the O O
autologous T O
repair T O
of O O
large D O
midline D O
incisional D O
hernias D O
by O O
restoring O O
the O O
functional O O
musculoaponeurotic O O
support O O
of O O
the O O
abdominal O O
wall O O

objective O O
and O O
importance O O
: O O
the O O
use O O
of O O
chronic T O
intrathecal T O
morphine T O
for O O
the O O
treatment O O
of O O
intractable D O
, D O
nonmalignant D D
pain D D
is O O
becoming O O
more O O
prevalent O O

methods O O
: O O
during O O
a O O
19-month O O
period O O
, O O
seven O O
children O O
with O O
empyema D O
underwent O O
thoracoscopy T O

< O O
to_see O O
> O O
we O O
describe O O
a O O
patient O O
with O O
left D O
cardiac D O
herniation D O
presenting O O
after O O
intrapericardial T O
pulmonectomy T O
for O O
primary D D
lung D D
cancer D D

the O O
growing O O
use O O
of O O
automated T O
night-time T T
dialysis T T
( T O
apd T O
) T O
in O O
peritoneal D T
dialysis D T
over O O
the O O
last O O
few O O
years O O
shows O O
that O O
this O O
method O O
represents O O
a O O
valid O O
alternative O O
to O O
continuous T O
ambulatory T O
peritoneal T T
dialysis T T
( T T
capd T T
) T T

la O O
serna O O
et O O
al O O
. O O
( O O
lancet O O
1987 O O
; O O
26 O O
: O O
1517 O O
) O O
were O O
the O O
first O O
to O O
treat O O
adults O O
with O O
recurrent D O
pericarditis D O
with O O
colchicine T O
, O O
and O O
were O O
followed O O
by O O
other O O
authors O O

while O O
these O O
findings O O
are O O
observed O O
for O O
all O O
classes O O
of O O
oral O O
drugs O O
, O O
the O O
issue O O
is O O
especially O O
critical O O
for O O
cancer D D
chemotherapy T D
, O O
in O O
which O O
a O O
narrow O O
therapeutic O O
index O O
is O O
frequently O O
observed O O

treatment O O
for O O
low-grade D O
nhl D O
during O O
the O O
past O O
30 O O
yr O O
has O O
consisted O O
of O O
high-dose T O
radiation T O
and O O
cytotoxic T O
agents T O
, O O
administered O O
alone O O
or O O
in O O
combination O O
, O O
and O O
high-dose T O
therapy T O
with T O
stem T O
cell T O
transplant T O

however O O
, O O
recent O O
clinical O O
use O O
of O O
monoclonal T O
antibodies T O
( T O
mabs T O
) T O
in O O
patients O O
with O O
low-grade D O
or D O
transformed D O
low-grade D O
nhl D O
has O O
resulted O O
in O O
less O O
toxicity O O
than O O
conventional O O
treatments O O
, O O
as O O
well O O
as O O
response O O
rates O O
that O O
are O O
comparable O O
or O O
superior O O
to O O
those O O
achieved O O
with O O
chemotherapy T T

therefore O O
, O O
interest O O
is O O
growing O O
in O O
mabs T O
as O O
therapeutic O O
alternatives O O
for O O
patients O O
with O O
low-grade D O
nhl D O
and O O
those O O
with O O
transformed O O
histology O O

conclusion O O
: O O
the O O
treatment O O
paradigm O O
for O O
nhl D O
is O O
expected O O
to O O
change O O
over O O
the O O
next O O
few O O
years O O
to O O
include O O
radiolabeled T O
mabs T O
, O O
administered O O
alone O O
or O O
in O O
combination O O
with O O
cytotoxic T O
agents T O

results O O
: O O
clinical O O
trials O O
of O O
uft T O
published O O
in O O
the O O
western O O
world O O
have O O
included O O
581 O O
patients O O
with O O
colorectal D D
cancer D D

the O O
activity O O
of O O
oral T O
uft T O
in O O
large-bowel D D
cancer D D
when O O
administered O O
with O O
oral T O
lv T O
( O O
approximately O O
50 O O
mg/dose O O
) O O
has O O
resulted O O
in O O
objective O O
response O O
rates O O
of O O
approximately O O
40 O O
% O O

conclusion O O
: O O
uft T O
is O O
a O O
fluoropyrimidine T O
active O O
in O O
colorectal D D
cancer D D

background O O
: O O
adrenalectomy T O
is O O
the O O
current O O
treatment O O
for O O
phaeochromocytoma D O

conclusion O O
: O O
adrenal-sparing T T
surgery T T
is O O
safe O O
and O O
effective O O
, O O
and O O
may O O
become O O
the O O
treatment O O
of O O
choice O O
in O O
patients O O
with O O
hereditary D O
phaeochromocytoma D O

< O O
to_see O O
> O O
purpose O O
: O O
the O O
purposes O O
of O O
this O O
descriptive O O
, O O
longitudinal O O
study O O
were O O
to O O
evaluate O O
the O O
macdibbs O O
mouth O O
assessment O O
instrument O O
for O O
the O O
assessment O O
of O O
mucositis O O
in O O
the O O
radiation T T
therapy T T
patient O O
being O O
treated O O
for O O
head D O
and D O
neck D O
cancer D O
and O O
to O O
describe O O
the O O
course O O
of O O
radiation-induced D O
mucositis D O
in O O
these O O
patients O O

< O O
to_see O O
> O O
as O O
concomitant D O
thrombocytosis D O
persisted O O
despite O O
treatment O O
with O O
hydroxyurea T O
, O O
the O O
new O O
megakaryocyte T O
inhibitor T O
anagrelide T O
( T O
agrelin T O
) T O
was O O
administered O O
and O O
led O O
to O O
normalization O O
of O O
the O O
platelet O O
count O O
within O O
11 O O
days O O

background O O
: O O
troglitazone T O
is O O
a O O
new O O
drug O O
for O O
the O O
treatment O O
of O O
type D O
2 D O
diabetes D D

< O O
to_see O O
> O O
for O O
a O O
subset O O
of O O
patients O O
with O O
kaposi D D
's D D
sarcoma D D
who O O
were O O
treated O O
with O O
recombinant T O
interferon T T
alfa-2a T T
, O O
the O O
disease O O
is O O
in O O
complete O O
remission O O
, O O
without O O
opportunistic D D
infection D D
, O O
and O O
they O O
appear O O
to O O
be O O
culture-negative O O
for O O
the O O
etiologic O O
retrovirus O O
that O O
causes O O
their O O
immune D O
deficiency D O

interferon T O
alfa-2a T O
appears O O
to O O
have O O
antineoplastic O O
efficacy O O
, O O
( O O
and O O
may O O
have O O
antiretroviral O T
efficacy O O
as O O
well O O
) O O
in O O
this O O
epidemic O O
neoplasm D O

in O O
three O O
consecutive O O
phase O O
ii O O
trials O O
of O O
recombinant T O
interferon T T
alfa-2a T T
( O O
rifn O O
alfa-2a O O
; O O
roferon-a O O
hoffmann-la O O
roche O O
, O O
nutley O O
, O O
nj O O
) O O
involving O O
96 O O
patients O O
with O O
advanced D D
malignant D D
melanoma D D
, O O
an O O
overall O O
response O O
rate O O
of O O
22 O O
% O O
was O O
observed O O

as O O
single O O
agent O O
therapy O O
in O O
malignant D D
melanoma D D
, O O
interferon T T
alfa-2a T T
was O O
only O O
marginally O O
useful O O
in O O
most O O
patients O O

studies O O
with O O
various O T
interferon T T
alpha T T
preparations T O
, O O
including O O
interferons T O
induced O O
in O O
human O O
leukocytes O O
, O O
interferon T T
alfa-n1 T T
, O T
interferon T T
alfa-2a T T
, O O
and O O
interferon T T
alfa-2b T T
, O O
have O O
all O O
provided O O
evidence O O
for O O
modest O O
but O O
reproducible O O
antitumor O O
activity O O
in O O
advanced D D
renal D D
cell D D
carcinoma D D

preliminary O O
evidence O O
suggests O O
that O O
interferons T O
beta T O
and T O
gamma T O
may O O
also O O
induce O O
regression O O
of O O
metastatic D D
renal D D
cell D D
carcinoma D D

the O O
rationale O O
for O O
antileukemic T O
therapy T O
in O O
hairy D O
cell D O
leukemia D O
is O O
to O O
reduce O O
the O O
significant O O
risk O O
of O O
infection O D
and O O
other O O
potential O O
serious O O
complications O O

splenectomy T O
presumably O O
alleviates O O
the O O
pancytopenic O O
effect O O
of O O
hypersplenism D O
by O O
removing O O
the O O
preferred O O
site O O
of O O
leukemic O O
cell O O
proliferation O O

recombinant O O
and O O
natural O O
forms O O
of O O
interferon T T
alpha T O
have O O
been O O
shown O O
to O O
bring O O
about O O
tumor O O
regressions O O
in O O
patients O O
with O O
low-grade D D
non-hodgkin D D
's D D
lymphoma D D

current O O
studies O O
using O O
interferon T T
in O O
patients O O
with O O
low-grade D D
non-hodgkin D D
's D D
lymphomas D D
are O O
evaluating O O
lower O O
, O O
and O O
perhaps O O
better O O
tolerated O O
doses O O
of O O
interferon T T

this O O
approach O O
is O O
being O O
extended O O
to O O
the O O
clinic O O
, O O
and O O
trials O O
are O O
now O O
underway O O
evaluating O O
combinations O O
of O O
interferon T T
and O O
various O O
cytotoxic T O
drugs T O
known O O
from O O
previous O O
studies O O
to O O
be O O
active O O
in O O
patients O O
with O O
low-grade D D
non-hodgkin D D
's D D
lymphomas D D

while O O
the O O
demonstrated O O
antiviral O O
, O O
antiproliferative O O
, O O
and O O
immunomodulatory O O
properties O O
of O O
interferons T O
have O O
led O O
to O O
a O O
number O O
of O O
theories O O
regarding O O
their O O
potential O O
use O O
in O O
treating O O
individuals O O
with O O
chronic D D
myelogenous D D
leukemia D D
( D D
cml D D
) D D
, O O
their O O
limited O O
availability O O
has O O
prevented O O
thorough O O
clinical O O
investigation O O

the O O
data O O
resulting O O
from O O
these O O
clinical O O
trials O O
indicate O O
that O O
interferon T T
alfa-2a T T
is O O
effective O O
in O O
inducing O O
hematologic O O
remissions O O
in O O
the O O
majority O O
of O O
minimally O O
treated O O
, O O
benign-phase D O
cml D O
, O O
ph1-positive O O
patients O O

more O O
than O O
1600 O O
patients O O
with O O
neoplastic D O
disorders D O
have O O
received O O
recombinant T O
human T O
interferon T T
alfa-2a T T
( T O
roferon-a T O
, T O
hoffmann-la T O
roche T O
, T O
nutley T O
, T O
nj T O
) T O
as O O
part O O
of O O
ongoing O O
or O O
completed O O
clinical O O
trials O O

purpose O O
: O O
a O O
phase O O
i/ii O O
trial O O
of O O
docetaxel T T
, O T
cisplatin T T
, O T
fluorouracil T T
( T T
5-fu T T
) T T
, O O
and O O
leucovorin T T
( T T
tpfl5 T T
) T T
induction T T
chemotherapy T T
for O O
patients O O
with O O
locally D D
advanced D D
squamous D D
cell D D
carcinoma D D
of D O
the D O
head D O
and D O
neck D O
( D O
scchn D O
) D O

patients O O
and O O
methods O O
: O O
twenty-three O O
previously O O
untreated O O
patients O O
with O O
stage D O
iii D O
or D O
iv D O
scchn D O
and O O
eastern O O
cooperative O O
oncology O O
group O O
functional O O
status O O
less O O
than O O
or O O
equal O O
to O O
2 O O
were O O
treated O O
with O O
tpfl5 T O

intrathecal T T
sufentanil T T
provides O O
approximately O O
2 O O
h O O
of O O
excellent O O
labor D O
analgesia O O
with O O
minimal O O
motor O O
blockade O O

objective O O
: O O
we O O
report O O
the O O
results O O
of O O
a O O
double-blind O O
, O O
double-dummy O O
, O O
active-control O O
study O O
designed O O
to O O
evaluate O O
the O O
efficacy O O
and O O
safety O O
of O O
lamotrigine T O
( T O
ltg T O
) T O
administered O O
as O O
monotherapy O O
to O O
adult O O
outpatients O O
with O O
partial D D
seizures D D

background O O
: O O
the O O
effectiveness O O
of O O
ltg T O
as O O
add-on O O
therapy O O
for O O
partial D D
seizures D D
in O O
adults O O
has O O
previously O O
been O O
established O O

conclusions O O
: O O
we O O
conclude O O
that O O
ltg T O
is O O
effective O O
and O O
well O O
tolerated O O
when O O
administered O O
as O O
monotherapy O O
in O O
adult O O
patients O O
with O O
partial D D
seizures D D

background O O
: O O
omega3 O O
fatty O O
acids O O
may O O
inhibit O O
neuronal O O
signal O O
transduction O O
pathways O O
in O O
a O O
manner O O
similar O O
to O O
that O O
of O O
lithium T O
carbonate T O
and O O
valproate T O
, O O
2 O O
effective O O
treatments O O
for O O
bipolar D O
disorder D O

the O O
present O O
study O O
was O O
performed O O
to O O
examine O O
whether O O
omega3 T O
fatty T O
acids T O
also O O
exhibit O O
mood-stabilizing O O
properties O O
in O O
bipolar D O
disorder D O

conclusion O O
: O O
omega3 T O
fatty T O
acids T O
were O O
well O O
tolerated O O
and O O
improved O O
the O O
short-term O O
course O O
of O O
illness O O
in O O
this O O
preliminary O O
study O O
of O O
patients O O
with O O
bipolar D O
disorder D O

several O O
large-scale O O
trials O O
have O O
firmly O O
established O O
the O O
effectiveness O O
of O O
thrombolytic T T
therapy T T
, O O
beta T O
blockers T O
, O O
and O O
aspirin T T
in O O
the O O
treatment O O
of O O
ami D O

< O O
to_see O O
> O O
while O O
diastolic D O
left D O
ventricular D O
( D O
lv D O
) D O
dysfunction D O
is O O
frequent O O
and O O
associated O O
with O O
cardiovascular D O
complications D O
in O O
end-stage D D
renal D D
disease D D
treated O O
with O O
dialysis T T
, O O
controversial O O
information O O
exists O O
on O O
diastolic O O
lv O O
function O O
after O O
renal O O
transplantation O O

methods O O
: O O
fluvastatin T O
40 O O
mg O O
daily O O
was O O
administered O O
to O O
25 O O
patients O O
with O O
hypercholesterolaemia D O
for O O
up O O
to O O
24 O O
weeks O O

the O O
inhibitory O O
effect O O
of O O
n-3 T O
polyunsaturated T O
fatty T O
acids T O
on O O
human D O
colorectal D D
cancer D D
has O O
been O O
speculated O O
on O O
from O O
epidemiological O O
data O O
and O O
animal O O
studies O O

we O O
conducted O O
a O O
long-term O O
trial O O
of O O
docosahexanoic T O
acid T O
( T O
dha T O
) T O
-concentrated T O
fish T O
oil T O
capsules T O
for O O
patients O O
in O O
a O O
high-risk O O
group O O
for O O
colorectal D D
cancer D D

three O O
patients O O
with O O
fap D O
and O O
two O O
patients O O
with O O
multiple O O
( O O
more O O
than O O
30 O O
) O O
colorectal D O
polyps D O
were O O
administered O O
dha-concentrated T O
fish T O
oil T O
capsules_hlk427554600 T O
( T O
2.2 T O
g T O
of T O
dha T O
and T O
0.6 T O
g T O
of T O
eicosapentanoic T O
acid T O
( T O
epa T O
) T O
per T O
day T O
) T O
for O O
one O O
or O O
two O O
years O O

this O O
article O O
reviews O O
current O O
trends O O
in O O
management O O
of O O
esophageal D O
achalasia D O
, O O
highlighting O O
short-term O O
outcome O O
and O O
cost O O
comparisons O O
of O O
three O O
treatments O O
: O O
botulinum T O
toxin T O
injection T O
, O O
pneumatic T O
dilation T O
, O O
and O O
laparoscopic T O
myotomy T O

the O O
clinical O O
application O O
of O O
therapeutic T O
hysteroscopy T O
, O O
mainly O O
in O O
the O O
field O O
of O O
the O O
treatment O O
of O O
abnormal D D
uterine D D
bleeding D D
, O O
started O O
in O O
the O O
1980s O O

< O O
to_see O O
> O O
in O O
this O O
article O O
, O O
evidence O O
of O O
effectiveness O O
and O O
cost-effectiveness O O
of O O
the O O
following O O
procedures O O
is O O
reviewed O O
: O O
( O O
1 O O
) O O
laser T O
treatment T O
of O O
bladder D D
tumors D D
; O O
( O O
2 O O
) O T
extracorporeal O T
shock-wave O T
lithotripsy O T
and O O
percutaneous O O
nephrolithotomy O O
; O O
( O O
3 O O
) O T
laparoscopic T T
treatment T T
of O O
endometriosis D D
; O O
( O O
4 O O
) O O
laparoscopic T O
removal T O
of O O
ovarian D O
cysts D O
; O O
( O O
5 O O
) O T
laparoscopic O T
cholecystectomy O T
; O O
( O O
6 O O
) O O
laparoscopic O O
appendectomy O O
; O O
( O O
7 O O
) O O
catheter T O
treatment T O
of O O
coronary D O
artery D O
disease D O
; O O
( O O
8 O O
) O O
palliation O O
of O O
colon O D
cancer O D
by O O
endoscopic O O
intervention O O
; O O
( O O
9 O O
) O O
treatment O O
of O O
upper D D
gastrointestinal D D
( D D
ugi D D
) D D
bleeding D D
by O O
endoscopic T O
intervention T O
; O O
and O O
( O O
10 O O
) O O
arthroscopic O O
knee O O
surgery O T

gene T T
therapy T T
of O O
malignant D D
brain D D
tumors D D

treatment O O
of O O
irritable D D
bowel D D
syndrome D D
with O O
chinese T O
herbal T O
medicine T O
: O O
a O O
randomized O O
controlled O O
trial O O

randomised O O
trial O O
of O O
interferon T T
alpha2b T T
plus T T
ribavirin T T
for O O
48 O O
weeks O O
or O O
for O O
24 O O
weeks O O
versus O O
interferon T T
alpha2b T T
plus T T
placebo T O
for O O
48 O O
weeks O O
for O O
treatment O O
of O O
chronic D D
infection D D
with D D
hepatitis D D
c D D
virus D D

low-molecular-weight T T
heparin T T
for O O
immediate O O
management O O
of O O
thromboembolic D O
disease D O
in O O
pregnancy O O

tubularized T O
incised T O
plate T O
hypospadias T O
repair T O
for O O
proximal D O
hypospadias D O

comparison O O
of O O
radical T O
prostatectomy T O
and O O
iodine T T
125 T T
interstitial T T
radiotherapy T T
for O O
the O O
treatment O O
of O O
clinically D O
localized D O
prostate D D
cancer D D
: O O
a O O
7-year O O
biochemical O O
( O O
psa O O
) O O
progression O O
analysis O O

the O O
effectiveness O O
of O O
acupuncture T O
in O O
treating O O
acute D D
dental D D
pain D D
: O O
a O O
systematic O O
review O O

correction O O
of O O
cardiac D D
defects D D
through O O
a O O
right T O
thoracotomy T T
in O O
children O O

new O O
technique O O
for O O
mesh T O
repair T O
of O O
paracolostomy D O
hernias D O

immunotherapy T O
of O O
tumors D O
with O O
autologous T O
tumor-derived T O
heat T O
shock T D
protein T D
preparations T D

comprehensive T O
modified T O
diet T O
simplifies O O
nutrition T O
management T O
of O O
adults O O
with O O
short-bowel D O
syndrome D O

extended O O
use O O
of O O
glatiramer T O
acetate T O
( T O
copaxone T O
) T O
is O O
well O O
tolerated O O
and O O
maintains O O
its O O
clinical O O
effect O O
on O O
multiple D D
sclerosis D D
relapse O D
rate O O
and O O
degree O O
of O O
disability O O

european O O
register O O
of O O
patients O O
with O O
sickle D O
cell D O
disease D O
treated O O
with O O
hydroxyurea T O
is O O
being O O
set O O
up O O

understanding O O
the O O
culture O O
of O O
prescribing O O
: O O
qualitative O O
study O O
of O O
general O O
practitioners O O
' O O
and O O
patients O O
' O O
perceptions O O
of O O
antibiotics T T
for O O
sore D D
throats D D

steroid T O
delivery T O
in O O
croup D O

haematoma T T
block T T
versus O O
intravenous T O
regional T O
anaesthesia T O
in O O
colles D O
' D O
fractures D O

direct T O
percutaneous T O
transluminal T O
angioplasty T O
for O O
acute D D
middle D D
cerebral D D
artery D D
occlusion D D

magnesium T O
sulphate T O
for O O
the O O
control O O
of O O
spasms D O
in D O
severe D O
tetanus D D

protective O O
effect O O
of O O
pralidoxime T O
on O O
muscle D D
fiber D D
necrosis D D
induced O O
by O O
organophosphate O O
compounds O O

assessment O O
of O O
atrioventricular T O
junction T O
ablation T O
and T O
vvir T O
pacemaker T O
versus O O
pharmacological T O
treatment T O
in O O
patients O O
with O O
heart D D
failure D D
and D O
chronic D D
atrial D D
fibrillation D D
: O O
a O O
randomized O O
, O O
controlled O O
study O O

statins T O
for O O
prevention O O
of O O
stroke D D

repair O O
of O O
ventral D O
hernias D O
with O O
expanded T O
polytetrafluoroethylene T O
patch T O

spinal T O
manipulation T O
in O O
the O O
treatment O O
of O O
episodic D O
tension-type D O
headache D O
: O O
a O O
randomized O O
controlled O O
trial O O

successful O O
treatment O O
with O O
lamivudine T O
for O O
fulminant D D
reactivated D D
hepatitis D D
b D D
infection D D
following O O
intensive T O
therapy T O
for O O
high-grade D O
non-hodgkin D D
's D D
lymphoma D D

influence O O
of O O
treatment O O
delay O O
on O O
infarct O O
size O O
and O O
clinical O O
outcome O O
in O O
patients O O
with O O
acute D D
myocardial D D
infarction D D
treated O O
with O O
primary T O
angioplasty T O

should O O
patients O O
with O O
advanced D D
sarcomas D D
be O O
treated O O
with O O
chemotherapy T T
? O O

plasma T O
exchange T O
and T O
tacrolimus-mycophenolate T O
rescue T O
for O O
acute D O
humoral D O
rejection D O
in O O
kidney O O
transplantation O O

hyperbaric T T
oxygen T T
therapy T T
for O O
children O O
with O O
cerebral D D
palsy D D

endoscopic T O
excision T O
of O O
a D O
forehead D O
mass D O

effect O O
of O O
photodynamic T O
therapy T O
in T O
combination T O
with T O
mitomycin T O
c T O
on O O
a O O
mitomycin-resistant D D
bladder D D
cancer D D
cell O O
line O O

is O O
conservative T O
surgery T T
for O O
tubal D O
pregnancy D O
preferable O O
to O O
salpingectomy T O
? O O
an O O
economic O O
analysis O O

laparoscopic T O
cornuostomy T O
in O O
the O O
treatment O O
of O O
interstitial D O
pregnancy D O
with O O
subsequent O O
hysterosalpingography O O

experimental O O
evaluation O O
of O O
the O O
use O O
of O O
recombinant T O
prourokinase T O
and O O
its O O
immobilized O O
forms O O
in O O
the O O
treatment O O
of O O
postoperative D D
fibrinoid D D
syndrome D D
in O O
ophthalmology O O

in O O
vitro O O
and O O
in O O
vivo O O
comparison O O
between O O
the O O
effects O O
of O O
treatment O O
with O O
adenosine T O
triphosphate T O
and O O
treatment O O
with O O
buthionine T O
sulfoximine T O
on O O
chemosensitization O O
and O O
tumour O O
growth O O
of O O
b16 D D
melanoma D D

effects O O
of O O
transpupillary T O
thermotherapy T O
on O O
immunological O O
parameters O O
and O O
apoptosis O O
in O O
a O O
case O O
of O O
primary D D
uveal D D
melanoma D D

is O O
there O O
a O O
rational O O
therapy O O
for O O
symptomatic O O
treatment O O
of O O
benign D O
prostatic D O
hyperplasia D O
with O O
phytogenic T O
drugs T O
? O O
illustrated O O
with O O
the O O
example O O
of O O
the O O
prostate O O
agent O O
from O O
serenoa O O
repens O O
( O O
sabal O O
fructus O O
) O O

pharmacological O O
and O O
clinical O O
effectiveness O O
of O O
a O O
fixed T O
phytogenic T O
combination T O
trembling T O
poplar T O
( T O
populus T O
tremula T O
) T O
, T O
true T O
goldenrod T O
( T O
solidago T O
virgaurea T O
) T O
and T O
ash T O
( T O
fraxinus T O
excelsior T O
) T O
in O O
mild D O
to D O
moderate D O
rheumatic D O
complaints D O

therapy O O
of O O
degenerative D O
diseases D O
of D O
the D O
musculoskeletal D O
system D O
with O O
south T O
african T O
devil T O
's T O
claw T O
( T O
harpagophytum T O
procumbens T O
dc T O
) T O

treatment O O
strategy O O
for O O
mucin-producing D O
intrahepatic D O
cholangiocarcinoma D O
: O O
value O O
of O O
percutaneous T T
transhepatic T T
biliary T T
drainage T T
and O O
cholangioscopy T O

strategy O O
for O O
surgical T T
management T T
of O O
ileocolonic D O
anastomotic D O
recurrence D O
in D O
crohn D D
's D D
disease D D

nerve-sparing T T
surgery T T
for O O
advanced D D
rectal D D
cancer D D
patients O O
: O O
special O O
reference O O
to O O
dukes O O
c O O
patients O O

prognostic O O
factors O O
in O O
patients O O
with O O
locally O D
advanced O D
rectal D D
adenocarcinoma D D
treated O O
with O O
preoperative T T
radiotherapy T T
and O T
surgery T T

current O O
surgical T T
therapy T T
for O O
bronchiectasis D O

thoracic T T
surgery T T
for O O
hydatid D O
disease D O

surgical T T
treatment T T
of O O
postpneumonic D O
empyema D O

thoracoscopic T T
surgery T T
for O O
pulmonary D D
tuberculosis D D

thoracoscopic T T
surgery T T
for O O
spontaneous D O
pneumothorax D O

surgery T O
for O O
chronic D D
thromboembolic D D
pulmonary D D
hypertension D D

transabdominal T O
extensive T O
esophagogastric T O
devascularization T O
with T O
gastroesophageal T O
stapling T O
for O O
management O O
of O O
noncirrhotic D D
portal D D
hypertension D D
: O O
long-term O O
results O O

surgical T T
treatment T T
for O O
lung D D
hydatid D D
disease D D

sliding T O
door T O
technique T O
for O O
the O O
repair O O
of O O
midline D O
incisional D O
hernias D O

one-lung T T
ventilation T T
in O O
patients O O
with O O
difficult D O
airways D O

thoracoscopy T O
for O O
empyema D O
in O O
children O O

sex O O
differences O O
in O O
the O O
use O O
of O O
asthma D D
drugs T D
: O O
cross O O
sectional O O
study O O

conventional T T
treatments T T
for O O
non-hodgkin D D
's D D
lymphoma D D
: O O
the O O
need O O
for O O
new O O
therapies O O

adrenal-sparing T T
surgery T T
for O O
phaeochromocytoma D O

antiplatelet T T
therapy T T
in O O
acute D D
cerebral D D
ischemia D D

laugier-hunziker D O
syndrome D O
: O O
case O O
report O O
and O O
treatment O O
with O O
the O O
q-switched T O
nd-yag T O
laser T O

thoracoscopic T O
operation T O
for O O
secondary D O
pneumothorax D O
under O O
local O O
and O O
epidural O O
anesthesia O O
in O O
high-risk O O
patients O O

troglitazone-induced D D
hepatic D D
failure D D
leading O O
to O O
liver T O
transplantation T O

a O O
modified O O
technique O O
of O O
tubeless O O
anaesthesia O O
for O O
microlaryngoscopy T O
and T O
bronchoscopy T O
in O O
young O O
children O O
with O O
stridor D O

a O O
randomized O O
trial O O
of O O
lactobacillus T O
acidophilus T O
bg2fo4 T O
to O O
treat O O
lactose D O
intolerance D O

treatment O O
of O O
idiopathic D O
thrombopenic D O
purpura D O
in O O
adolescents O O
by O O
intravenous T O
immunoglobulin T O

azithromycin T T
therapy T T
for O O
scrub D O
typhus D O
during O O
pregnancy O O

excimer T T
laser T T
assisted T T
in T O
situ T O
keratomileusis T O
for O O
hyperopia D O

three O O
consecutive O O
phase O O
ii O O
studies O O
of O O
recombinant T O
interferon T T
alfa-2a T T
in O O
advanced D D
malignant D D
melanoma D D

interferon T O
treatment T O
of O O
renal D D
cell D D
carcinoma D D

current O O
and O O
future O O
uses O O
of O O
recombinant T O
interferon T T
alpha T T
in O O
the O O
treatment O O
of O O
low-grade D D
non-hodgkin D D
's D D
lymphoma D D

antimicrobial T T
treatment T T
options O O
in O O
the O O
management O O
of O O
odontogenic D O
infections D O

recombinant T O
glycoprotein T T
vaccine T T
for O O
the O O
prevention O O
of O O
genital D O
hsv-2 D D
infection D D
: O O
two O O
randomized O O
controlled O O
trials O O

induction T T
chemotherapy T T
with T T
docetaxel T T
, T T
cisplatin T T
, T O
fluorouracil T O
, T O
and T O
leucovorin T T
for O O
squamous D D
cell D D
carcinoma D D
of O O
the O O
head O O
and O O
neck O O
: O O
a O O
phase O O
i/ii O O
trial O O

low-dose T D
steroids T D
reduce O D
flu-like D D
symptoms D D
at O O
the O O
initiation O O
of O O
ifnbeta-1b O O
in O O
relapsing-remitting O O
ms O O

study O O
of O O
three O O
different O O
doses O O
of O O
epidural T O
neostigmine T O
coadministered T O
with T O
lidocaine T O
for O O
postoperative D O
analgesia D O

an O O
active-control O O
trial O O
of O O
lamotrigine T O
monotherapy T O
for O O
partial D D
seizures D D

< O O
to_see O O
> O O
safety O O
of O O
intrathecal T O
sodium T O
nitroprusside T O
for O O
the O O
treatment O O
and O O
prevention O O
of O O
refractory D D
cerebral D D
vasospasm D D
and D O
ischemia D O
in O O
humans O O

the O O
effect O O
of O O
heliox T O
in O O
acute D D
severe D D
asthma D D
: O O
a O O
randomized O O
controlled O O
trial O O
. O O

long-term O O
survival O O
of O O
patients O O
with O O
unresectable D D
colorectal D D
cancer D D
liver D D
metastases D D
following O O
infusional T T
chemotherapy T T
with T O
5-fluorouracil T O
, T O
leucovorin T T
, T O
oxaliplatin T O
and T O
surgery T T

< O O
to_see O O
> O O
fatal D O
acute D O
haemolysis D O
in O O
an O O
aids D D
patient O O
treated O O
with O O
lindinavir T O

a O T
simplified O T
laparoscopic T T
technique T T
for T O
mesh T O
placement T O
in O O
ventral D O
hernia D O
repair O O

pharmacological T O
management T O
of O O
acute D D
myocardial D D
infarction D D

mesenteric D D
venous D D
thrombosis D D
: O O
successful O O
treatment O O
by O O
intraarterial T O
lytic T O
therapy T O

gene T T
therapy T T
for O O
myocardial D O
angiogenesis D O

dipyridamole T T
plus T T
aspirin T T
in O O
cerebrovascular D D
disease D D

what O O
is O O
the O O
real O O
role O O
of O O
cd40 O O
in O O
cancer D D
immunotherapy T D
? O O

the O O
effects O O
of O O
oral T O
liarozole T O
on O O
epidermal O D
proliferation O O
and O O
differentiation O O
in O O
severe D O
plaque D D
psoriasis D D
are O O
comparable O O
with O O
those O O
of O O
acitretin T O
. O O

safety O O
and O O
potential O O
effectiveness O O
of O O
daunorubicin-containing T O
liposomes T O
in O O
patients O O
with O O
advanced D D
recurrent D D
malignant D D
cns D D
tumors D D

an O O
experimental O O
application O O
of O O
gene T O
therapy T O
for O O
human D O
retinoblastoma D D

acid T T
suppression T T
therapy T T
in O O
barrett D O
's D O
esophagus D O
: O O
the O O
importance O O
of O O
ph O O
monitoring O O

surgical T O
approaches T O
to O O
pediatric D O
defecatory D D
disorders D D

lutein T O
improves O O
visual O O
function O O
in O O
some O O
patients O O
with O O
retinal D D
degeneration D D
: O O
a O O
pilot O O
study O O
via O O
the O O
internet O O

drug O O
information O O
questions O O
and O O
answers O O
: O O
new O O
for O O
psoriasis D D
: O O
colchicine T O

ippb T O
in O O
severe D O
pulmonary D D
emphysema D D
: O O
limited O O
applications O O

long-term O O
mortality O O
in O O
patients O O
after O O
a O O
british O O
trial O O
of O O
anticoagulants T O
in O O
acute D D
myocardial D D
infarction D D

our O O
results O O
in O O
the O O
surgical T T
treatment T T
of O O
habitual D O
shoulder D O
dislocation D O
with O O
special O O
reference O O
to O O
occupational O D
disability O D

alkaline O O
phosphatase O O
in O O
neutrophil O O
leukocytes O O
of O O
patients O O
with O O
infectious D O
mononucleosis D O
and O O
the O O
effect O O
of O O
corticosteroid T T
therapy T T

surgical T T
treatment T T
of O O
uterine D D
cervix D D
insufficiency D D
during O O
the O O
2d O O
trimester O O
of O O
pregnancy O O

physiologic T O
treatment T O
of O O
depressive D O
reactions D O
: O O
a O O
pilot O O
study O O

the O O
use O O
of O O
quinidine T O
sulphate T O
for O O
the O O
treatment O O
of O O
atrial D O
fibrillation D O
in O O
twelve O O
horses O O

synergism O O
in O O
the O O
chemotherapy T T
of O O
eimeria D O
infections D O
of O O
chicks O O

treatment O O
of O O
hydrocele D O
and D O
cysts D O
of D O
the D O
epididymis D O
with O O
sclerosing T O
injections T O
of T O
quinine T O
and T O
urea T O
chlorhydrolactate T O
in O O
a O O
30 O O
per O O
cent O O
solution O O

the O O
single-place T O
caisson T O
in O O
the O O
treatment O O
of O O
decompression D O
accidents D O

blood O O
volume O O
measurements O O
in O O
burn D O
therapy T O

phenylbutazone T O
and O O
acute D D
leukemia D D
. O O

the O O
place O O
of O O
surgery T T
in O O
hypertrophic D O
obstructive D O
cardiomyopathy D D
( D D
idiopathic D D
hypertrophic D D
subaortic D D
stenosis D D
) D D

the O O
treatment O O
of O O
autoimmune D D
hemolytic D D
anemia D D
with O O
heparin T T

effects O O
of O O
clomiphene T O
citrate T O
on O O
endometrial D O
hyperplasia D O
in O O
the O O
premenopausal O O
female O O

prolonged O O
use O O
of O O
methyldopa T T
in O O
severe D O
hypertension D D
in O O
pregnancy O O

the O O
effects O O
of O O
social O O
class O O
and O O
friends O O
' O O
expectations O O
on O O
oral O T
polio D T
vaccination T T
participation O T

glutathione O O
s-transferase O O
activity O O
in O O
epithelial D D
ovarian D D
cancer D D
: O O
association O O
with O O
response O O
to O O
chemotherapy T T
and O O
disease O O
outcome O O

interferon-alpha-2b T O
in O O
the O O
management O O
of O O
patients O O
with O O
relapsed O O
and/or O O
refractory O D
hodgkin D D
's D D
disease D D

< O O
to_see O O
> O O
frontal D T
dysfunction D T
blocks O T
the O O
therapeutic O O
effect O O
of O O
tha T O
on O O
attention O O
in O O
alzheimer D D
's D D
disease D D

effects O O
of O O
clomipramine T O
on O O
plasma O O
amino O O
acids O O
and O O
serotonergic O O
parameters O O
in O O
panic D O
disorder D O
and D O
depression D O
. O O

thalidomide T T
for O O
aphthous D D
ulcers D D
in O O
hiv D D
infection D D

aspirin T O
therapy T O
in O O
diabetes D D
mellitus D D

combined T O
pancreas-/kidney T O
transplantation T O
as O O
a O O
standard O O
procedure O O
in O O
therapy O O
of O O
kidney D O
failure D O
in D O
type D O
i D O
diabetic D D
patients D O

corticosteroid T O
injections T O
for O O
sciatica D O

flutamide T O
plus T O
castration T O
in O O
patients O O
with O O
previously O O
untreated O D
prostate D D
cancer D D

the O O
immediate O O
effectiveness O O
of O O
electrical T T
nerve T T
stimulation T T
and O T
electrical T T
muscle T T
stimulation T T
on O O
myofascial D D
trigger D D
points D D

in O O
vitro O O
radiation-induced O O
apoptosis O O
and O O
tumour O O
response O O
to O O
radiotherapy T O
: O O
a O O
prospective O O
study O O
in O O
patients O O
with O O
non-hodgkin D D
lymphomas D D
treated O O
by O O
low-dose T O
irradiation T T

drug T O
therapy T O
for O O
coronary D D
heart D D
disease D D
: O O
the O O
sheffield O O
table O O

percutaneous T O
drainage T O
of O O
hydatid D O
cysts D O

surgery T O
for O O
ectopia D O
lentis D O

< O O
to_see O O
> O O
antiplatelet T T
therapy T T
to O O
prevent O O
stroke D D
: O O
risk O O
of O O
brain D D
hemorrhage D D
and O O
efficacy O O
in O O
atrial T D
fibrillation T D

high-dose T O
chemotherapy T T
with T O
autologous T O
hematopoietic T O
stem-cell T O
support T O
for O O
breast D D
cancer D D
in O O
north O O
america O O

is O O
concomitant T T
radiotherapy T T
and T T
chemotherapy T T
superior O T
to O T
optimal O T
radiotherapy T T
alone O O
in O O
anal D D
cancer D D
? O O

standard T O
versus T O
high-dose T O
therapy T O
in O O
10+ O O
breast D D
cancer D D

anal O O
continence O O
after O O
surgery T T
for O O
rectal D O
prolapse D O

aspirin T O
therapy T O
for O O
cardiovascular D D
disease D D

dosing O O
of O O
amoxicillin/clavulanate T O
for O O
treatment O O
of O O
lower D O
respiratory D D
tract D D
infection D D

pharmacoeconomic O O
analysis O O
of O O
ampicillin-sulbactam T O
versus O O
cefoxitin T O
in O O
the O O
treatment O O
of O O
intraabdominal D O
infections D O

new T O
therapies T O
for O O
severe D O
meningococcal D O
disease D O

another O O
potential O O
use O O
of O O
troglitazone T O
in O O
noninsulin-dependent D D
diabetes D D
mellitus D D

< O O
to_see O O
> O O
jaw D O
clenching D O
following O O
gamma T O
knife T O
treatment T O
for O O
trigeminal D O
neuralgia D O

the O O
protective O O
effect O O
of O O
condoms T O
and O O
nonoxynol-9 T O
against O O
hiv D D
infection D D

evaluation O O
of O O
adjuvant T O
psychological T O
therapy T O
in O O
patients O O
with O O
testicular D D
cancer D D
: O O
randomised O O
controlled O O
trial O O

the O O
effect O O
of O O
an O O
endothelin-receptor T O
antagonist T O
, T O
bosentan T O
, O O
on O O
blood O O
pressure O O
in O O
patients O O
with O O
essential D D
hypertension D D
. O O

guidelines O O
for O O
the O O
use O O
of O O
antiretroviral T T
agents T T
in O O
hiv D O
-infected O O
adults O O
and O O
adolescents O O

long-term O O
therapy O O
with O O
long-acting T O
octreotide T O
( T O
sandostatin-lar T O
) T O
for O O
the O O
management O O
of O O
acromegaly D O

are O O
abvd T O
and O O
mopp/abv T O
truly O O
equivalent O O
for O O
treating O O
hodgkin D O
's D O
disease D O
at O O
advanced O O
stages O O
? O O

paclitaxel T O
for O O
the O O
treatment O O
of O O
lymphoma D O

montelukast T O
, T O
a T O
leukotriene-receptor T O
antagonist T O
, T O
for O O
the O O
treatment O O
of O O
mild D O
asthma D D
and D O
exercise-induced D O
bronchoconstriction D O

atypical O O
antipsychotic T O
agents T O
in O O
the O O
treatment O O
of O O
schizophrenia D O
and D O
other D O
psychiatric D D
disorders D D

percutaneous T O
transluminal T O
angioplasty T O
in O O
the O O
treatment O O
of O O
renovascular D D
hypertension D D
: O O
sequential O O
prospective O O
study O O

esophageal T O
intubation T O
for O O
palliative O T
treatment O T
in O O
advanced D D
carcinoma D D
of D O
the D O
esophagus D O
and D O
cardia D O

pathological O O
staging O O
and O O
biochemical O O
recurrence O O
after O O
neoadjuvant T O
androgen T O
deprivation T O
therapy T O
in O O
combination O O
with O O
radical T O
prostatectomy T O
in O O
clinically O O
localized O O
prostate D D
cancer D D

how O O
often O O
does O O
surgery T T
for O O
peptic D D
ulceration D D
eradicate O D
helicobacter O D
pylori O D
? O O
systematic O O
review O O
of O O
36 O O
studies O O

a O O
comparison O O
of O O
noninvasive T T
positive-pressure T T
ventilation T T
and O O
conventional T O
mechanical T T
ventilation T T
in O O
patients O O
with O O
acute D D
respiratory D D
failure D D

long-term O O
safety O O
and O O
effectiveness O O
of O O
iron-chelation T O
therapy T O
with T O
deferiprone T O
for O O
thalassemia D O
major D O

positron O O
emission O O
tomography O O
in O O
assessing O O
response O O
to O O
neoadjuvant T T
chemotherapy T T
for O O
non-small-cell D D
lung D D
cancer D D

reconstruction O O
of O O
thoracic O D
wall O D
defects O D
after O D
tumor D D
resection T T
using O O
a O O
polytetrafluoroethylene O O
soft O O
tissue O O
( O O
gore-tex O O
) O O
patch O O

a O O
comparison O O
of O O
rectal T O
diazepam T O
gel T O
and O O
placebo O O
for O O
acute D D
repetitive D D
seizures D D

effect O O
of O O
long-term O O
salmeterol T O
treatment T O
on O O
exercise-induced D D
asthma D D

randomized O O
trial O O
of O O
intensive T T
cyclophosphamide T T
, T O
epirubicin T O
, T O
and T O
fluorouracil T T
chemotherapy T T
compared O O
with O O
cyclophosphamide T O
, T O
methotrexate T O
, T O
and T O
fluorouracil T O
in O O
premenopausal O O
women O O
with O O
node-positive D D
breast D D
cancer D D

acute O D
effect O O
of O O
lorazepam T O
on O O
respiratory O O
muscles O O
in O O
patients O O
with O O
chronic D D
obstructive D D
pulmonary D D
disease D D

low-molecular-weight T O
heparins T O
in O O
the O O
treatment O O
of O O
venous D O
thromboembolism D O

5-year O O
outcome O O
of O O
surgical T T
resection T T
and O O
watchful O O
waiting O O
for O O
men O O
with O O
moderately O O
symptomatic O O
benign D O
prostatic D O
hyperplasia D O
: O O
a O O
department O O
of O O
veterans O O
affairs O O
cooperative O O
study O O

for O O
how O O
long O O
should O O
antipsychotic T O
medication T O
be O O
continued O O
after O O
the O O
first O O
psychotic D O
episode D O
in D O
schizophrenics D O
? O O

ida-flag T O
( T O
idarubicin T O
, T O
fludarabine T O
, T O
cytarabine T O
, T O
g-csf T O
) T O
, O O
an O O
effective O O
remission-induction T O
therapy T O
for O O
poor-prognosis D O
aml D O
of D O
childhood D O
prior O O
to O O
allogeneic O O
or O O
autologous O O
bone O O
marrow O O
transplantation O O
: O O
experiences O O
of O O
a O O
phase O O
ii O O
trial O O

< O O
to_see O O
> O O
effects O O
of O O
anal T O
invasive T O
treatment T O
and O O
incontinence D O
on O O
mental O O
health O O
and O O
psychosocial O O
functioning O O
of O O
adolescents O O
with O O
hirshsprung D O
's D O
disease D O
and O O
low O O
anorectal D O
anomalies D O

single O O
or O O
double O O
lung T O
transplantation T O
for O O
pulmonary D D
hypertension D D

interferon T O
beta T O
treatment T O
for O O
multiple D D
sclerosis D D

ten-year O O
disease O O
free O O
survival O O
after O O
transperineal T O
sonography-guided T O
iodine-125 T O
brachytherapy T O
with O O
or O O
without O O
45-gray T O
external T O
beam T O
irradiation T T
in O O
the O O
treatment O O
of O O
patients O O
with O O
clinically O O
localized O O
, O O
low O O
to O O
high O D
gleason D D
grade D D
prostate D D
carcinoma D D

partial O O
or O O
near O O
total O O
pancreatectomy T O
for O O
persistent D O
neonatal D O
hyperinsulinaemic D O
hypoglycaemia D O
: O O
the O O
pathologist O O
's O O
role O O

radical T O
prostatectomy T O
for O O
prostate D D
cancer D D
: O O
the O O
perineal O O
approach O O
increases O O
the O O
risk O O
of O O
surgically O O
induced O O
positive O O
margins O O
and O O
capsular O O
incisions O O

open T O
capsulorrhaphy T O
with T O
suture T T
anchors T O
for O O
recurrent D O
anterior D O
dislocation D O
of D O
the D O
shoulder D O

intravenous T T
immunoglobulin T T
treatment T T
in O O
multiple D D
sclerosis D D

randomised O O
trial O O
of O O
irinotecan T T
versus O O
fluorouracil T O
by O O
continuous O O
infusion O O
after O O
fluorouracil O O
failure O O
in O O
patients O O
with O O
metastatic D D
colorectal D D
cancer D D

the O O
effectiveness O O
of O O
intraocular T O
pressure T O
reduction T O
in O O
the O O
treatment O O
of O O
normal-tension D O
glaucoma D O

perceived O O
contraindications O O
to O O
thrombolytic T T
treatment T T
in O O
acute D D
myocardial D D
infarction D D

lignocaine T O
or O O
bupivacaine T O
for O O
digital D O
ring D O
block D O

steroids T O
in O O
lateral D O
epicondylitis D O

steroids T O
in O O
de D O
quervain D O
's D O
tenosynovitis D O

antibiotics T T
after O O
dog D O
bite D O

immobilisation T O
after O O
first O O
anterior O O
shoulder D O
dislocation D O

stereotactic T O
radiosurgery T O
for O O
acoustic D O
neuroma D O
: O O
a O O
canadian O O
perspective O O

anticytokine T T
therapy T T
-- O O
a O O
new O O
era O O
in O O
the O O
treatment O O
of O O
rheumatoid D D
arthritis D D
? O O

control O O
of O O
the O O
malignant D O
hyperpyrexic D O
syndrome D O
in O O
mhs O O
swine O O
by O O
dantrolene T O
sodium T O

hematopoietic T O
stem-cell T O
transplantation T O
for O O
the O O
treatment O O
of O O
severe D O
combined D O
immunodeficiency D O

low-dose T O
clozapine T O
for O O
the O O
treatment O O
of O O
drug-induced D O
psychosis D O
in D O
parkinson D D
's D D
disease D D

comparing O O
the O O
efficacy O O
and O O
safety O O
of O O
fluoxetine T O
and O O
venlafaxine T T
in O O
outpatient D O
depression D O

cost-effectiveness O O
of O O
interferon T T
treatment T T
for O O
hepatitis D D
c D D

hyperbaric T T
oxygen T T
therapy T T
for O O
children O O
with O O
cerebral D D
palsy D D

peripheral T O
retinal T O
cryotherapy T O
for O O
postvitrectomy D D
diabetic D D
vitreous D D
hemorrhage D D
in O O
phakic O O
patients O O

hyperbaric T T
or T O
normobaric T O
oxygen T O
for O O
acute D D
carbon D D
monoxide D D
poisoning D D
: O O
a O O
randomised O O
controlled O O
clinical O O
trial O O

multicentre O O
clinical O O
evaluation O O
of O O
vigabatrin T O
( T O
sabril T O
) T O
in O O
mild D O
to D O
moderate D O
partial D O
epilepsies D O

matrix T O
metalloproteinase T O
inhibitors T O
in O O
the O O
treatment O O
of O O
cancer D D

high O T
dose O T
cyclophosphamide T T
with O T
carboplatin T T
: O O
a O O
tolerable O O
regimen O O
suitable O O
for O O
dose O O
intensification O O
in O O
children O O
with O O
solid D D
tumors D D

microsurgical T O
treatment T O
of O O
supratentorial D D
cavernous D D
malformations D D

microsurgical T O
treatment T O
of O O
infratentorial D O
malformations D O

stereotactic T O
radiosurgery T O
for O O
management O O
of O O
deep D D
brain D D
cavernous D D
malformations D D

interferon-antibodies T O
and O O
the O O
breakthrough O O
phenomenon O O
during O O
ribavirin/interferon-alpha T T
combination T T
therapy T T
and O O
interferon-alpha T O
monotherapy T O
of O O
patients O O
with O O
chronic D D
hepatitis D D
c D D

treatment O O
of O O
barrett D O
esophagus D O
with O O
argon T O
plasma T O
coagulation T O
with T O
acid T O
suppression T O
-- O O
a O O
prospective O O
study O O

meta-analysis O O
of O O
typhoid D D
vaccine T T
efficacy O O
trials O O
showed O O
that O O
whole O O
cell O O
vaccines O T
are O O
more O O
effective O O
than O O
either O O
the O O
oral O O
, O O
attenuated O T
vaccine O T
or O O
the O O
vi O T
polysaccharide O T
vaccine O T

experimental O T
vaccination T T
against O O
mycoplasma D O
agalactiae D O
using O O
different O O
inactivated O O
vaccines O T

a O O
randomized O O
, O O
controlled O O
study O O
in O O
adults O O
of O O
the O O
immunogenicity O O
of O O
a O O
novel O O
hepatitis D T
b D T
vaccine T T
containing O T
mf59 O T
adjuvant O T

immunogenicity O O
of O O
three O O
haemophilus D D
influenzae D D
type D D
b D D
protein O D
conjugate O T
vaccines T T
in O O
hiv O O
seropositive O O
adults O O
and O O
analysis O O
of O O
predictors O O
of O O
vaccine O T
response O O

vaccination T O
against O O
schistosoma D D
mansoni D D
infection D D
using O O
74 O O
kda O O
schistosoma O O
protein O O
antigen O O

phase O O
1 O O
safety O O
and O O
immune O O
response O O
studies O O
of O O
a O O
dna T O
vaccine T T
encoding O T
hepatitis D T
b D T
surface O T
antigen O O
delivered O O
by O O
a O O
gene O O
delivery O O
device O O

protection O O
of O O
swine O O
from O O
foot-and-mouth D O
disease D O
with O O
one O O
dose O O
of O O
an O O
all-d T O
retro T O
peptide T O

intranasal T O
immunization T O
with O O
chlamydia D D
trachomatis D D
, D O
serovar D O
e D O
, O O
protects O O
from O O
a O O
subsequent O O
vaginal O O
challenge O O
with O O
the O O
homologous O O
serovar O O

mutants O O
of O O
cholera O O
toxin O O
as O O
an O O
effective O O
and O O
safe O O
adjuvant O O
for O O
nasal D D
influenza D D
vaccine T T

field O O
evaluation O O
of O O
the O O
clinical O O
effectiveness O O
of O O
vaccines T T
against O O
pertussis D O
, D O
measles D O
, D O
rubella D O
and D O
mumps D O
: O O
comments O O

transmural T O
drainage T O
of O O
pancreatic D O
fluid D O
collections D O
without O O
electrocautery O O
using O O
the O O
seldinger O O
technique O O

echocardiography-guided T O
ethanol T O
septal T O
reduction T O
for O O
hypertrophic D O
obstructive D O
cardiomyopathy D D

alterations O O
of O O
monocyte O O
function O O
in O O
patients O O
with O O
growth D O
hormone D O
( D O
gh D O
) D O
deficiency D O
: O O
effect O O
of O O
substitutive O O
gh T O
therapy T O

comparison O O
of O O
the O O
effects O O
of O O
salmeterol T O
and O O
ipratropium T O
bromide T O
on O O
exercise O O
performance O O
and O O
breathlessness O O
in O O
patients O O
with O O
stable D D
chronic D D
obstructive D D
pulmonary D D
disease D D
. O O

< O O
to_see O O
> O O
safety O O
trial O O
with O O
the O O
5ht1b/1d T O
agonist T O
avitriptan T O
( O O
bms-180048 O O
) O O
in O O
patients O O
with O O
migraine D D
who O O
have O O
experienced O O
pressure D O
, D O
tightness D D
, D O
and/or D O
pain D O
in O O
the O O
chest O O
, O O
neck O O
, O O
and/or O O
throat O O
following O O
sumatriptan T O

double O O
blind O O
, O O
cluster O O
randomised O O
trial O O
of O O
low O O
dose O O
supplementation O O
with O O
vitamin T O
a T O
or O O
beta T O
carotene T O
on O O
mortality D O
related D O
to D O
pregnancy D O
in O O
nepal O O
. O O

medical T T
treatments T T
for O O
balding D O
in O O
men O O

carbon D D
monoxide D D
poisoning D D
treated O O
with O O
hyperbaric T O
oxygen T O
: O O
metabolic O O
acidosis O O
as O O
a O O
predictor O O
of O O
treatment O O
requirements O O

medication T O
received O O
by O O
patients O O
with O O
depression D O
following O O
the O O
acute O O
episode O O
: O O
adequacy O O
and O O
relation O O
to O O
outcome O O

< O O
to_see O O
> O O
reduced D O
bone D O
density D O
at O O
completion O O
of O O
chemotherapy T T
for O O
a O O
malignancy D O

< O O
to_see O O
> O O
surgical-site D O
complications D O
associated O O
with O O
a O O
morphine T T
nerve T T
paste T T
used O O
for O O
postoperative D D
pain D D
control D O
after D O
laminectomy D O

splenectomy T O
during O O
pregnancy O O
: O O
an O O
option O O
in O O
the O O
treatment O O
of O O
autoimmune D D
thrombocytopenic D D
purpura D D

melatonin T O
treatment T O
of O O
sleep-wake D O
cycle D O
disorders D O
in O O
children O O
and O O
adolescents O O

randomized O O
phase O O
ii O O
study O O
of O O
the O O
neurokinin T O
1 T O
receptor T O
antagonist T O
cj-11 T O
, T O
974 T O
in O O
the O O
control O O
of O O
cisplatin-induced D O
emesis D O

cataract D D
surgery T D
and O O
its O O
effect O O
on O O
intraocular O O
pressure O O

the O O
outcome O O
of O O
arthroscopic T O
treatment T O
of O O
temporomandibular D O
joint D O
arthropathy D O

neostigmine T O
for O O
acute D D
colonic D D
pseudo-obstruction D D

new O T
vaccine T T
targets O D
childhood D D
pneumonia D D

a O O
comparison O O
of O O
botulinum T O
toxin T O
and O O
nitroglycerin T O
ointment T O
for O O
chronic D O
anal D O
fissure D O

< O O
to_see O O
> O O
the O O
effect O O
of O O
bisoprolol T O
on O O
perioperative D O
mortality D O
and O O
myocardial D D
infarction D D
in O O
high-risk O O
patients O O
undergoing O O
vascular T T
surgery T T

surgical T T
management T T
of O O
severe D O
secondary D O
peritonitis D O

early T O
surgical T T
treatment T T
for O O
supratentorial D O
intracerebral D O
hemorrhage D O
: O O
a O O
randomized O O
feasibility O O
study O O

evaluation O O
of O O
clomipramine T O
as O O
an O O
adjunct O O
to O O
behavioural T O
therapy T O
in O O
the O O
treatment O O
of O O
separation-related D O
problems D O
in O O
dogs O O

nice O O
to O O
rule O O
on O O
influenza D D
flu D D
drug O T
zanamivir T T

< O O
to_see O O
> O O
longitudinal D O
melanonychia D O
associated O O
with O O
hydroxyurea T O
therapy T O
in O O
a O O
patient O O
with O O
essential D O
thrombocytosis D O

biologic O O
markers O O
as O O
predictors O O
of O O
clinical O O
outcome O O
from O O
systemic T O
therapy T O
for O O
primary O D
operable O D
breast D D
cancer D D

treatment O O
of O O
hypertension D D
with O O
ascorbic T O
acid T O

postoperative D O
peritonitis D O
originating O O
from O O
the O O
duodenum O O
: O O
operative O O
management O O
by O O
intubation T O
and T O
continuous T O
intraluminal T O
irrigation T O

efficacy O O
of O O
open-bite D O
treatment O O
with O O
the O O
thera-spoon T O

< O O
to_see O O
> O O
pompholyx D O
( D O
vesicular D O
eczema D O
) D O
after O O
i.v T O
. T O
immunoglobulin T O
therapy T O
for O O
neurologic D D
disease D D

mitomycin T O
, T O
ifosfamide T T
, T O
and T O
cisplatin T T
in O O
unresectable D D
non-small-cell D D
lung D D
cancer D D
: O O
effects O O
on O O
survival O O
and O O
quality O O
of O O
life O O
. O O

hepatic O T
arterial O T
infusion O T
of O T
chemotherapy T T
after O O
resection T T
of O T
hepatic D T
metastases D T
from O O
colorectal D D
cancer D D

waiting O O
for O O
the O O
definitive O O
trial O O
of O O
hepatic T T
arterial T T
chemotherapy T T
for O O
colorectal D D
cancer D D

phase O O
iii O O
randomized O O
study O O
of O O
cisplatin T T
versus O T
paclitaxel T T
versus O T
cisplatin T T
and T T
paclitaxel T T
in O O
patients O O
with O O
suboptimal O O
stage O O
iii O O
or O O
iv O O
ovarian D D
cancer D D
: O O
a O O
gynecologic O O
oncology O O
group O O
study O O

evidence O O
for O O
double O O
resistance O O
to O O
permethrin T O
and T O
malathion T O
in O O
head D O
lice D O

urgent O O
colonoscopy T O
for O O
the O O
diagnosis O O
and O O
treatment O O
of O O
severe D O
diverticular D D
hemorrhage D D

treatment O O
of O O
parkinson D D
's D D
disease D D
should O O
begin O O
with O O
a O O
dopamine T O
agonist T O

< O O
to_see O O
> O O
ulceration D O
in O O
an O O
ileocolic D O
anastomosis D O
treated O O
with O O
ranitidin T O

low-molecular-weight T T
heparin T T
vs O T
heparin T T
in O O
the O O
treatment O O
of O O
patients O O
with O O
pulmonary D D
embolism D D

radiotherapy T T
in O O
breast-conserving T O
treatment T O
for O O
ductal D D
carcinoma D D
in O O
situ O O
: O O
first O O
results O O
of O O
the O O
eortc O O
randomised O O
phase O O
iii O O
trial O O
10853 O O

methadone T T
maintenance T T
vs O T
180-day O T
psychosocially O T
enriched O T
detoxification T T
for O O
treatment O O
of O O
opioid D O
dependence D O
: O O
a O O
randomized O O
controlled O O
trial O O

cryogen O O
spray O O
cooling O O
during O O
nd T O
: T O
yag T T
laser T T
treatment T T
of O O
hemangiomas D O

effects O O
of O O
tolcapone T O
, T O
a T O
catechol-o-methyltransferase T O
inhibitor T O
, O O
on O O
motor O D
symptoms O D
and O O
pharmacokinetics O O
of O O
levodopa T O
in O O
patients O O
with O O
parkinson D D
's D D
disease D D
. O O

gene T T
therapy T T
for O O
cancer D D

therapeutic O O
effects O O
of O O
ldl T O
apheresis T O
in O O
the O O
prevention O O
of O O
atherosclerosis D O

dry T O
powdered T O
formoterol T O
, O O
twice O O
a O O
day O O
versus O O
aerosolized T O
salbutamol T O
, O O
four O O
times O O
a O O
day O O
, O O
in O O
patients O O
with O O
stable D D
asthma D D

cell-based T T
vaccination T T
against O O
melanoma D D
-- O O
background O O
, O O
preliminary O O
results O O
, O O
and O O
perspective O O

celecoxib T O
for O O
arthritis D D

poliomyelitis D O
prevention O O
: O O
revised O O
recommendations O O
for O O
use O O
of O O
inactivated O O
and O O
live O T
oral O T
poliovirus D T
vaccines T T

mesh O O
plug O O
repair O O
and O O
groin D T
hernia D T
surgery T T

brimonidine T O
tartrate T O
0.2 O O
% O O
twice O O
daily O O
vs O O
timolol T O
0.5 O O
% O O
twice O O
daily O O
: O O
1-year O O
results O O
in O O
glaucoma D O
patients O O

ticarcillin/clavulanate T O
versus O O
imipenem/cilistatin T O
for O O
the O O
treatment O O
of O O
infections D O
associated D O
with D O
gangrenous D O
and D O
perforated D O
appendicitis D O

is O O
zero O O
dose O O
oral O T
polio D T
vaccine T T
effective O O
in O O
preterm O O
babies O O
? O O

an O O
economic O O
analysis O O
of O O
different O O
strategies O O
of O O
immunization T O
against O O
hepatitis D D
a D D
virus D D
in O O
developed O O
countries O O

issues O O
and O O
challenges O O
with O O
antithrombotic T O
therapy T O
in O O
diabetic O D
patients O O
with O O
acute D D
coronary D D
syndromes D D

global O O
risk O O
assessment O O
for O O
lipid T O
therapy T O
to O O
prevent O O
coronary D D
heart D D
disease D D

the O O
role O O
of O O
fibric T O
acid T O
derivatives T O
in O O
the O O
secondary O O
prevention O O
of O O
coronary D D
heart D D
disease D D

epoetin T O
: O O
a O O
pharmacoeconomic O O
review O O
of O O
its O O
use O O
in O O
chronic D D
renal D D
failure D D
and O O
its O O
effects O O
on O O
quality O O
of O O
life O O

rationale O O
for O O
the O O
use O O
of O O
antiplatelet T O
drugs T O
in O O
patients O O
with O O
peripheral D D
vascular D D
disease D D

the O O
fluoroquinolones T O
for O O
urinary D D
tract D D
infections D D
: O O
a O O
review O O

reduction O O
of O O
vasoreactivity D O
and O O
thrombogenicity D O
with O O
laser-thermal T O
angioplasty T O
: O O
comparison O O
with O O
balloon T O
angioplasty T O

effects O O
of O O
ultrasound T O
energy T O
on O O
total D O
peripheral D O
artery D O
occlusions D O
: O O
initial O O
angiographic O O
and O O
angioscopic O O
results O O
. O O

high-dose T O
chemotherapy T T
with T O
autologous T O
stem-cell T O
support T O
for O O
epithelial D D
ovarian D D
cancer D D

pelvic T T
floor T T
stimulation T T
in O O
the O O
treatment O O
of O O
adult D O
urinary D D
incontinence D D

chronic T T
vagus T T
nerve T T
stimulation T T
for O O
treatment O O
of O O
seizures D D

`` T T
tandem T T
'' T T
high-dose T T
chemoradiotherapy T T
with T O
autologous T O
stem-cell T O
support T O
in O O
the O O
treatment O O
of O O
newly O O
diagnosed O O
or O O
responsive O O
multiple D O
myeloma D O

special O O
report O O
: O O
comparative O O
efficacy O O
of O O
different O O
types O O
of O O
pneumatic T O
compression T O
pumps T O
for O O
the O O
treatment O O
of O O
lymphedema D O

